{"name":"aTyr Pharma, Inc.","slug":"atyr-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":190000,"revenueGrowth":-19.1,"grossMargin":0,"rdSpend":60219000,"netIncome":-74118000,"cash":93003000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATYR1940","genericName":"ATYR1940","slug":"atyr1940","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ATYR1940","genericName":"ATYR1940","slug":"atyr1940","phase":"phase_1","mechanism":"ATYR1940 is designed to modulate immune and inflammatory responses involved in fibrotic disease processes.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPeURtMDBqMkV1c3hJTzFYY2ZIRHd0S0lLZmxLVk5wbFl3N1ppQWllRk9oNlc1QURGdW15bmtUUm1jSlRIVnFkRHl1TnVkNW9PZkVwVTZwaXVTU0FUaEFvaW9LcDNlSEZoR3NLNkNoa3l1WmdDYlBpTjJDOVJOckZzcmc5YnZRcGVxRzlkTkt5NFJQTlJIYk9DSlY3em1wUGZFYkFZTjJnQTZQVVJNVG1jQ19nSQ?oc=5","date":"2026-03-26","type":"regulatory","source":"Stock Titan","summary":"aTyr Pharma (NASDAQ: ATYR) seeks approval to double share authorization - Stock Titan","headline":"aTyr Pharma (NASDAQ: ATYR) seeks approval to double share authorization","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQTUNDWFFab1FLOFJrLTNkS2xfSERPUW5LM0t6Z0hhU1hmcjFmOC05WWEzOFpob2NOamZqRGo1bFl4SUl5Z3FiTVpxNEV0N19xNTdzNWNyMEx5T1dYRXJYY1cydlRDTzBDMlFZMWt4QUJHazZodENfOXcwNmdOQmhyQWpPWG1ueEFvcFVwVUc5OG5vQ1ZDaGZBYm9EZk5CdWgzZTJEWDcxSHNvXzN1ZFJ6UFM1Z0lDV3NUS0Jwd3dpTHJuZ05VeWtDMFh2SQ?oc=5","date":"2026-03-26","type":"pipeline","source":"Stock Titan","summary":"Vanguard disaggregates holdings; reports 0 shares in aTyr Pharma (ATYR) - Stock Titan","headline":"Vanguard disaggregates holdings; reports 0 shares in aTyr Pharma (ATYR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcHZTQjNkRTR1TFllLWhFOGdOczRNVjc3bVh5Y2NFV21pdHZkNFp2SXJpNXAyZXY5aXBuZnNWR3ozal9sZkZUN29tdVJWUVFTUlotSldFTHJLNnhwZDBqRXg5WW1rRXJQdHozUEIwdFBLSnJyNjB6aTdrNzRjMFNzdkZVTHhYWmlpWTBsX1ptWGdqZ2lQb29yb1RIeUlCMEFEMnB4Q041al9YRXVKNGZwX3ZKZ3VLczVIZDV5b2pZQkx6OVp2THNPb2lMVDNTOUQxOVhDaEMtTk5jS0pmanExRUo5MklqdGFVOGM2dE10Y0xOTzRhZy0yWg?oc=5","date":"2026-03-05","type":"earnings","source":"GlobeNewswire","summary":"aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - GlobeNewswire","headline":"aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZmV2aHZNX2NTZm05UGd3UHVKVkxHQjdCUVBiSUl4MlZzOUhubDZpOVJleFJMWk0tbFEzOWQ0THh4eEE2eGdEQVVYbTRoaGpzc3d6eF9MWDBYS1l3czNZeXlleG1mNTkwOFp6bGxqSXprT3U1djdpdEhXYmRhaUtOd2kzeDZQbHpfSWExSzNxR183emd5UGktUFFrYzdVanViOXFpbTlTNjlURHhjdjhBMFg2MDVyYndRNElQNU4xc2c?oc=5","date":"2026-03-05","type":"regulatory","source":"Stock Titan","summary":"After key study miss, FDA to weigh aTyr lung disease drug in April - Stock Titan","headline":"After key study miss, FDA to weigh aTyr lung disease drug in April","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNVS02b1l4V2hZY0I3WmNBVGZObVlpc1NnQS1PRlhZNlRzUlBjM0JyVFFwSjB4YURoZlgzMHlFQUNmRXB2eGNLWHl6TGtmYktTWjZRME9lOGdaaEUxdWxoUFZQaFQ1VXJuTWZ4OEVtcVFfREl2dm9TMWc3ZTdWUlBkNGZQeXQtWUZSMHJ6UGthOGtST2ViY2hxS2w1UjVYWE9fdExSWVUxUTRnZ1p3S21lNUsxVE5JeThjS3ZIb213VXBNU2JSX2JfVk5tZkswSC0zOU50dU1QMUxleXJpd3d3?oc=5","date":"2026-02-20","type":"pipeline","source":"GlobeNewswire","summary":"aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire","headline":"aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-18","type":"pipeline","source":"simplywall.st","summary":"aTyr Pharma Insiders Added US$926.8k Of Stock To Their Holdings - simplywall.st","headline":"aTyr Pharma Insiders Added US$926.8k Of Stock To Their Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPb0s2dFpmek9heFVSMUhEYmVfM2g4bDdaY2l2dHNJUTE3ZHNnTHlZTlE2MF9sV2Z1V1VmU0lYaGs2WXNJNkZuUkJIRzc3UDRuaWZKbzQxbjN6ekgxN3dJWjItVlFESjBIa1YyUFVHUVlpWEdXYndXZ1dfN1NCUW84NEczY2JLSkhyelE?oc=5","date":"2026-02-18","type":"deal","source":"Yahoo Finance","summary":"aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - Yahoo Finance","headline":"aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPeDgwR21tNGIzVUlpcGozdURuMDNPWGZYUU11Vkh2WTl5N0N5ek9hdzZxTERoeUNTa29ydFlKVjVKZlo4YzB4el8zU3pQZTBWMEFsRGF4WW5QZGRiVm8tRVpZMzRfcW5mVF82UnJEYmRIOVNIQlJ6RnEzYVcxa2RneE5B?oc=5","date":"2026-02-03","type":"regulatory","source":"Seeking Alpha","summary":"aTyr Pharma gets FDA meeting on lead drug (ATYR:NASDAQ) - Seeking Alpha","headline":"aTyr Pharma gets FDA meeting on lead drug (ATYR:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE8tR1ZsSF9fZU9hb3hYcXBPRjg0emVmNWo1R0o3VGd1WnpRTDNxbVYzZUhFeFV5dUNtSTJQY2xPcVgwXy1RUVNaR0JGWkIxZDRDMW0waVotQ2VSNURPMmR1M3VSQXJuRkM4dDV4bXFPZmpvZzNyaWVydy0yRWZIeW8?oc=5","date":"2026-01-11","type":"pipeline","source":"Yahoo Finance","summary":"Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance","headline":"Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans?","sentiment":"neutral"},{"date":"2025-12-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQS1pJelFZdnRBX3NSRzJhUVFDdldBeTlST0ZuXzhtYzdwdWxKUjVFTXhiMTJ2Y2JBWk9kT09YNGc4cXhDYm5ENzF3ZzVWaXBJTXlHSkhZa29CdmFxU3M0TDl6UHlTYU42M1pfTy1VeFJkQVNYVkhmb3pkdllVYUtpNjRpY1d6R2JwMlBESTlBUlhwU2JhdTNiT2ZtVEtVcU9jb2tGSEVQVWJGUXVPSy1lRVhGcHE4LXMwbzgwSTh4dWlSMWVXeW94Tkp1SjJZamZ5TFhuU2paUXljNmJHM2I3MXRSTG9WQklOUUJyRWdGWFRyVDlTb1RWeGhPQTJTSlh3ZkZuSjE4Qno?oc=5","date":"2025-11-18","type":"pipeline","source":"PR Newswire","summary":"ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman - PR Newswire","headline":"ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":190000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":190000,"period":"2025-12-31"},{"value":235000,"period":"2024-12-31"},{"value":235000,"period":"2024-12-31"},{"value":353000,"period":"2023-12-31"},{"value":353000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":60219000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-74118000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":93003000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}